PRECIS: We retrospectively reviewed records of patients prescribed latanoprostene bunod to assess its efficacy and safety in a real-world clinical setting. Latanoprostene bunod was efficacious in lowering intraocular pressure and had a favorable safety profile. PURPOSE: To evaluate the usage of latanoprostene bunod 0.024%, the first topical nitric oxide donating prostaglandin analog for reducing intraocular pressure, in clinical practice. PATIENTS AND METHODS: Retrospective review identified patients prescribed latanoprostene bunod by 5 glaucoma specialists at an academic center from 1/2018-11/2019. 56 patients (102 eyes) met inclusion criteria of an intraocular pressure measured at the visit latanoprostene bunod was prescribed and at 2 visits ≥7 days after beginning treatment, with no surgeries, lasers or medication changes during follow-up. Main outcome measures were intraocular pressure, number of ocular medications, and adverse effects. RESULTS: Intraocular pressure (mean±standard deviation mmHg) at the visit latanoprostene bunod was prescribed was 16.2±4.3 on 3.2±1.5 glaucoma medications. IOP at most recent visit was 13.7±3.8 on 3.2±1.6 medications. Mean intraocular pressure reduction was 2.1±3.5 (P<0.0001) at first follow-up, after 38.7±36.5 days, and 2.5±3.3 (P<0.0001) at last follow-up, after 235.9±160.8 days. Pressure decreased ≥2▒mmHg in 60%, ≥3▒mmHg in 46%, and ≥4▒mmHg in 34% of eyes. All patients received latanoprostene bunod as replacement for a prostaglandin analog or latanoprost/netarsudil fixed-dose combination. 43 patients remained on latanoprostene bunod throughout the follow-up period. 7 were discontinued for insufficient pressure control, 4 for adverse effects including pain and itching, and 2 for financial reasons. CONCLUSIONS: In two years of clinical use of latanoprostene bunod, patients exhibited intraocular pressure reductions that were statistically significant overall and clinically meaningful in 60% of patients. Latanoprostene bunod was well-tolerated and may be more efficacious than traditional prostaglandin analogs.
PRECIS: We retrospectively reviewed records of patients prescribed latanoprostene bunod to assess its efficacy and safety in a real-world clinical setting. Latanoprostene bunod was efficacious in lowering intraocular pressure and had a favorable safety profile. PURPOSE: To evaluate the usage of latanoprostene bunod 0.024%, the first topical nitric oxide donating prostaglandin analog for reducing intraocular pressure, in clinical practice. PATIENTS AND METHODS: Retrospective review identified patients prescribed latanoprostene bunod by 5 glaucoma specialists at an academic center from 1/2018-11/2019. 56 patients (102 eyes) met inclusion criteria of an intraocular pressure measured at the visit latanoprostene bunod was prescribed and at 2 visits ≥7 days after beginning treatment, with no surgeries, lasers or medication changes during follow-up. Main outcome measures were intraocular pressure, number of ocular medications, and adverse effects. RESULTS: Intraocular pressure (mean±standard deviation mmHg) at the visit latanoprostene bunod was prescribed was 16.2±4.3 on 3.2±1.5 glaucoma medications. IOP at most recent visit was 13.7±3.8 on 3.2±1.6 medications. Mean intraocular pressure reduction was 2.1±3.5 (P<0.0001) at first follow-up, after 38.7±36.5 days, and 2.5±3.3 (P<0.0001) at last follow-up, after 235.9±160.8 days. Pressure decreased ≥2▒mmHg in 60%, ≥3▒mmHg in 46%, and ≥4▒mmHg in 34% of eyes. All patients received latanoprostene bunod as replacement for a prostaglandin analog or latanoprost/netarsudil fixed-dose combination. 43 patients remained on latanoprostene bunod throughout the follow-up period. 7 were discontinued for insufficient pressure control, 4 for adverse effects including pain and itching, and 2 for financial reasons. CONCLUSIONS: In two years of clinical use of latanoprostene bunod, patients exhibited intraocular pressure reductions that were statistically significant overall and clinically meaningful in 60% of patients. Latanoprostene bunod was well-tolerated and may be more efficacious than traditional prostaglandin analogs.